Search
EHA Research Conference
On this page, you will find the Sponsor Program for the EHA Research Conference 2024. If the Sponsor Program does not display correctly, please click here or download the file. Click here to learn more about the meeting.
Read moreEHA-SfPM Precision Medicine Meeting
On this page, you will find the Sponsor Program for the EHA-SfPM Precision Medicine Meeting. If the Sponsor Program does not display correctly, please click here or download the file.
Read moreRegistration
Register here
The registration fee for the ESH-EBMT-EHA 3rd Translational Research Conference: Bone Marrow Failure and Leukaemia Predisposition Syndromes is:
– 600€ for fully trained
– 300€ for in-training *
– 300€ Allied Health Professionals
– 600€ for Corporate
*A proof will be requested to confirm your status.…
ESH-EBMT-EHA 3rd Translational Research Conference
ESH-EBMT-EHA 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes
Date: November 15-17, 2024
Location: Paris, France
Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour
With the support of the Severe Aplastic…
Scientific Meetings
The EHA-SWG Scientific Meetings have been developed as a joint effort of the EHA Specialized Working Groups (SWGs) and EHA to intensify the beneficial collaboration.
Read moreEHA response to the EU’s Pharma Revision
Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.
Read moreMeeting Program
For the program please click here.
If you would like a printable / PDF version of the program, you can download it via the 'Scientific Programme' tab in the above linked planner.
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read moreHelping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- »